Javier García‐Samaniego

The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm

Homie Razavi, Imam Waked, Christoph Sarrazin et al. · Journal of Viral Hepatitis · 2014 · 484 citations · Full text

Veterinary Medicine, Infectious Diseases, Pharmacotherapy +16

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Stephen A. Harrison, Vincent Wai‐Sun Wong, Takeshi Okanoue et al. · Journal of Hepatology · 2020 · 466 citations

Medicine, Internal Medicine, Pharmacotherapy +12

Peginterferon-Alfa2a Plus Ribavirin for 48 Versus 72 Weeks in Patients With Detectable Hepatitis C Virus RNA at Week 4 of Treatment

José M. Sánchez–Tapias, M. Diago, P Escartín et al. · Gastroenterology · 2006 · 360 citations · Full text

Pharmacy, Infectious Diseases, Pharmacotherapy +15

Incidence and Predictors of Severe Liver Fibrosis in Human Immunodeficiency Virus–Infected Patients with Chronic Hepatitis C: A European Collaborative Study

Luz Martín‐Carbonero, Yves Benhamou, Massimo Puoti et al. · Clinical Infectious Diseases · 2003 · 272 citations · Full text

Medicine, Infectious Diseases, Pathology +17

A randomized, placebo-controlled trial of emricasan in patients with NASH and F1-F3 fibrosis

Stephen A. Harrison, Zachary Goodman, Abdul Jabbar et al. · Journal of Hepatology · 2019 · 251 citations

Medicine, Internal Medicine, Pathology +10